Examining the cross-reactivity and neutralization mechanisms of a panel of mAbs against adeno-associated virus serotypes 1 and 5
Open accessThe DOI matches its Crossref record; 72 of the 74 references it cites were found in a registry or an index.
Abstract
Neutralizing antibodies play a central role in the prevention and clearance of viral infections, but can be detrimental to the use of viral capsids for gene delivery. Antibodies present a major hurdle for ongoing clinical trials using adeno-associated viruses (AAVs); however, relatively little is known about the antigenic epitopes of most AAV serotypes or the mechanism(s) of antibody-mediated neutralization. We developed panels of AAV mAbs by repeatedly immunizing mice with AAV serotype 1 (AAV1) capsids, or by sequentially immunizing with AAV1 followed by AAV5 capsids, in order to examine the efficiency and mechanisms of antibody-mediated neutralization. The antibodies were not cross-reactive between heterologous AAV serotypes except for a low level of recognition of AAV1 capsids by the AAV5 antibodies, probably due to the initial immunization with AAV1. The neutralization efficiency of different IgGs varied and Fab fragments derived from these antibodies were generally poorly neutralizing. The antibodies appeared to display various alternative mechanisms of neutralization, which included inhibition of receptor-binding and interference with a post-attachment step.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several studies have shown that following AAV administration, antibodies produced in response were cross-reactive against other non-administered AAV capsid variants [71–73].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [73]
Citations
Cites
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 1×
“Successful outcomes of AAV gene delivery have also been realized by direct injection into partially immune privileged tissues such as the retinal pigment epithelium (Maguire et al., 2008).”
BackgroundClades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., & Wilson, J. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6381-6388.2004 · Cited by 1,070 · cited 1×
“The different serotypes of AAV have viral proteins (VPs) that are ~60–90 % identical in amino acid sequence (Gao et al., 2003, 2004), with variations in capsid surface-oriented loops, resulting in alterations of antigenicity, tissue tropism and transduction efficiency (Govindasamy et al., 2006;…”
BackgroundBoutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970 · cited 3×
“…to virus neutralization has been recognized as a major barrier to clinical trials involving AAV in humans, and the role of cellular immunity is also becoming increasingly appreciated (Boutin et al., 2010; Breous et al., 2011; Calcedo et al., 2009; Mingozzi & High, 2011; van der Marel et al., 2011).”
BackgroundAdeno-associated Virus Serotypes: Vector Toolkit for Human Gene Therapy
Wu, Z., Asokan, A., & Samulski, R. J. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.05.009 · Cited by 922 · cited 3×
“…as vectors for therapeutic gene delivery due to features that make them potentially attractive vectors, including high capsid stability and lack of pathogenicity (Allocca et al., 2006; Dai & Rabie, 2007; Grimm & Kay, 2003; Michelfelder & Trepel, 2009; Van Vliet et al., 2008; Wu et al., 2006b).”
BackgroundWorldwide epidemiology of neutralizing antibodies to adeno-associated viruses
Calcedo, R., Vandenberghe, L. H., Gao, G., Lin, J., & Wilson, J. M. (2009) · The Journal of Infectious Diseases · doi:10.1086/595830 · Cited by 808 · cited 2×
“…to virus neutralization has been recognized as a major barrier to clinical trials involving AAV in humans, and the role of cellular immunity is also becoming increasingly appreciated (Boutin et al., 2010; Breous et al., 2011; Calcedo et al., 2009; Mingozzi & High, 2011; van der Marel et al., 2011).”
BackgroundBurger, C., Gorbatyuk, O. S., Velardo, M. J., Peden, C. S., Williams, P., Zolotukhin, S., Reier, P. J., Mandel, R. J., & Muzyczka, N. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.05.024 · Cited by 741 · cited 2×
“Other serotypes such as AAV1 and AAV5 have been less well characterized, but show enhanced transduction of certain tissues such as muscle, brain and/or haematopoietic stem cells compared with AAV2 (Burger et al., 2004; Chao et al., 2000; Davidson et al., 2000; Zabner et al., 2000; Zhong et al., 2006).”
BackgroundMarks, W. J., Bartus, R. T., Siffert, J., Davis, C. S., Lozano, A., Boulis, N., Vitek, J., Stacy, M., Turner, D., Verhagen, L., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70254-4 · Cited by 684 · cited 1×
“The AAV2 serotype is the best characterized and is also the capsid type with the largest number of ongoing clinical gene therapy trials (e.g. Grieger & Samulski, 2005; Marks et al., 2010; Mueller & Flotte, 2008; Scallan et al., 2003).”
BackgroundSui, J., Li, W., Murakami, A., Tamin, A., Matthews, L. J., Wong, S. K., Moore, M. J., Tallarico, A. S. C., Olurinde, M., Choe, H., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307140101 · Cited by 550 · cited 1×
“The cells were washed extensively with cold growth medium and assayed for viral binding compared with a control well with no antibody added as measured by Alexa-488 fluorescence intensity using flow cytometry (Sui et al., 2004).”
MethodGene therapy vectors based on adeno-associated virus type 1
Xiao, W., Chirmule, N., Berta, S. C., McCullough, B., Gao, G., & Wilson, J. M. (1999) · Journal of Virology · doi:10.1128/jvi.73.5.3994-4003.1999 · Cited by 541 · cited 2×
“…antibodies can be formed after initial gene therapy application, and strategies for avoiding interference with those during a second round of delivery antibodies include administration of transgenes packaged by different, non-cross-reactive AAV serotypes (Halbert et al., 2000; Xiao et al., 1999).”
BackgroundDavidson, B. L., Stein, C. S., Heth, J. A., Martins, I., Kotin, R. M., Derksen, T. A., Zabner, J., Ghodsi, A., & Chiorini, J. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3428 · Cited by 531 · cited 13×
“Studies of AAV2 examining a small number of mAbs or polyclonal anti-capsid antibodies show that antibody binding is affected by changes in a small number of amino acid positions within variable loops on the capsid surface (Huttner et al., 2003; Lochrie et al., 2006; Maersch et al., 2010; Moskalenko et al., 2000; Wobus…”
InfluentialSelf-citation
Research works printed but not linked: 2
- 10.1073/pnas.050581197 · DOI · Paper page
- Kerr, 2006, Parvoviruses
Cited by
Tse, L. V., Klinc, K. A., Madigan, V. J., Castellanos Rivera, R. M., Wells, L. F., Havlik, L. P., Smith, J. K., Agbandje-McKenna, M., & Asokan, A. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1704766114 · Cited by 210
“An earlier study showed that 4E4 and 5H7 reduce AAV1 transduction by affecting both the binding and postattachment steps essential for host cell transduction (6).”
BackgroundMethodSelf-citationImmunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer
Arjomandnejad, M., Dasgupta, I., Flotte, T. R., & Keeler, A. M. (2023) · BioDrugs · doi:10.1007/s40259-023-00585-7 · Cited by 159
Tseng, Y.-S., & Agbandje-McKenna, M. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00009 · Cited by 134
“This is because the MAb was generated only 4 days after AAV5 capsid immunization of a mouse that had been previously immunized with AAV1 (56).”
BackgroundInfluentialSelf-citationCapsid antibodies to different adeno-associated virus serotypes bind common regions
Gurda, B. L., DiMattia, M. A., Miller, E. B., Bennett, A., McKenna, R., Weichert, W. S., Nelson, C. D., Chen, W.-J., Muzyczka, N., Olson, N. H., et al. (2013) · Journal of Virology · doi:10.1128/jvi.00622-13 · Cited by 127
Self-citationMoreno, A. M., Palmer, N., Alemán, F., Chen, G., Pla, A., Jiang, N., Leong Chew, W., Law, M., & Mali, P. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0431-2 · Cited by 125
Hareendran, S., Balakrishnan, B., Sen, D., Kumar, S., Srivastava, A., & Jayandharan, G. R. (2013) · Reviews in Medical Virology · doi:10.1002/rmv.1762 · Cited by 113
“antibodies against AAV1 and AAV6 cross react efficiently indicating that they are closely related serotypes whereas AAV4, which is the most antigenically divergent serotype, is not neutralised by any other anti-sera [43,44].”
BackgroundGreenberg, B., Butler, J., Felker, G. M., Ponikowski, P., Voors, A. A., Pogoda, J. M., Provost, R., Guerrero, J., Hajjar, R. J., & Zsebo, K. M. (2016) · Gene Therapy · doi:10.1038/gt.2015.109 · Cited by 111
Strategy to detect pre-existing immunity to AAV gene therapy
Falese, L., Sandza, K., Yates, B., Triffault, S., Gangar, S., Long, B., Tsuruda, L., Carter, B., Vettermann, C., Zoog, S. J., et al. (2017) · Gene Therapy · doi:10.1038/gt.2017.95 · Cited by 101
Characterization of the Adeno-Associated Virus 1 and 6 Sialic Acid Binding Site
Huang, L.-Y., Patel, A., Ng, R., Miller, E. B., Halder, S., McKenna, R., Asokan, A., & Agbandje-McKenna, M. (2016) · Journal of Virology · doi:10.1128/jvi.00161-16 · Cited by 101
“AAV1 capsids (56, 75) and the B1 MAb that reacts against denatured AAV”
BackgroundSelf-citationMapping a Neutralizing Epitope onto the Capsid of Adeno-Associated Virus Serotype 8
Gurda, B. L., Raupp, C., Popa-Wagner, R., Naumer, M., Olson, N. H., Ng, R., McKenna, R., Baker, T. S., Kleinschmidt, J. A., & Agbandje-McKenna, M. (2012) · Journal of Virology · doi:10.1128/jvi.00218-12 · Cited by 93
Self-citationStructure of the gene therapy vector, adeno-associated virus with its cell receptor, AAVR
Meyer, N. L., Hu, G., Davulcu, O., Xie, Q., Noble, A. J., Yoshioka, C., Gingerich, D. S., Trzynka, A., David, L., Stagg, S. M., et al. (2019) · eLife · doi:10.7554/elife.44707 · Cited by 83
Majowicz, A., Salas, D., Zabaleta, N., Rodríguez-Garcia, E., González-Aseguinolaza, G., Petry, H., & Ferreira, V. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.05.003 · Cited by 73
A systematic review of immunosuppressive protocols used in AAV gene therapy for monogenic disorders
Vrellaku, B., Hassan, I. S., Howitt, R., Webster, C. P., Harriss, E., McBlane, F., Betts, C., Schettini, J. L., Lion, M., Mindur, J. E., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.07.016 · Cited by 84
Tseng, Y.-S., Gurda, B. L., Chipman, P., McKenna, R., Afione, S., Chiorini, J. A., Muzyczka, N., Olson, N. H., Baker, T. S., Kleinschmidt, J., et al. (2015) · Journal of Virology · doi:10.1128/jvi.02710-14 · Cited by 70
“The overlap of the ADK1a epitope with those for 4E4 and 5H7 (Tables 2 and 3) also suggests that it may act by blocking cellular receptor attachment/cell surface binding, as previously reported for these two MAbs (65).”
BackgroundSelf-citationThe Effect of CpG Sequences on Capsid-Specific CD8+ T Cell Responses to AAV Vector Gene Transfer
Xiang, Z., Kurupati, R. K., Li, Y., Kuranda, K., Zhou, X., Mingozzi, F., High, K. A., & Ertl, H. C. J. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.11.014 · Cited by 67
Strategies to circumvent humoral immunity to adeno-associated viral vectors
Tse, L. V., Moller-Tank, S., & Asokan, A. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1035645 · Cited by 61
“One such extrinsic factor that limits the clinical impact of AAV-based gene therapy is the prevalence of pre-existing neutralizing antibodies (NAbs) to AAVs in the human population due to natural infection or crossreactivity of NAbs between different AAV subtypes [16,17].”
BackgroundLugin, M. L., Lee, R. T., & Kwon, Y. J. (2020) · ACS Nano · doi:10.1021/acsnano.0c03850 · Cited by 65
Identification and Mutagenesis of the Adeno-Associated Virus 5 Sialic Acid Binding Region
Afione, S., DiMattia, M. A., Halder, S., Di Pasquale, G., Agbandje-McKenna, M., & Chiorini, J. A. (2015) · Journal of Virology · doi:10.1128/jvi.02503-14 · Cited by 58
“tently, two of the three mouse monoclonal IgG antibodies available for AAV5, 3C5 and ADK5a, are nonneutralizing (34, 35) (data not shown).”
BackgroundSelf-citationGorovits, B., Azadeh, M., Buchlis, G., Harrison, T., Havert, M., Jawa, V., Long, B., McNally, J., Milton, M., Nelson, R., et al. (2021) · The AAPS Journal · doi:10.1208/s12248-021-00628-3 · Cited by 53
Parvoviruses: Structure and Infection
Halder, S., Ng, R., & Agbandje-McKenna, M. (2012) · Future Virology · doi:10.2217/fvl.12.12 · Cited by 54
Self-citationIdentification of an adeno-associated virus binding epitope for AVB sepharose affinity resin
Wang, Q., Lock, M., Prongay, A. J., Alvira, M. R., Petkov, B., & Wilson, J. M. (2015) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2015.40 · Cited by 50
Cryo-electron Microscopy of Adeno-associated Virus
Stagg, S. M., Yoshioka, C., Davulcu, O., & Chapman, M. S. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00936 · Cited by 50
Jose, A., Mietzsch, M., Smith, J. K., Kurian, J., Chipman, P., McKenna, R., Chiorini, J., & Agbandje-McKenna, M. (2019) · Journal of Virology · doi:10.1128/jvi.01394-18 · Cited by 44
“Monoclonal antibodies binding to the 3-fold region of different AAV serotypes, e.g., AAV1-5H7 (9, 30), AAV1-ADK1a (11), AAV2-C37B (9, 25), AAV6-ADK6 (13), and AAV8-ADK8 (10), neutralize the transduction capability of the respective AAV serotype.”
BackgroundSelf-citationPre-Clinical Assessment of Immune Responses to Adeno-Associated Virus (AAV) Vectors
Basner-Tschakarjan, E., Bijjiga, E., & Martino, A. T. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00028 · Cited by 39
“The cross-reactivity of αAAV1 or αAAV5 antibodies was tested against a dot blot containing AAV1,AAV2,AAV4, AAV5, AAV6, AAV7, AAV8, AAV9 capsid.”
InfluentialAn Emerging Adeno-Associated Viral Vector Pipeline for Cardiac Gene Therapy
Asokan, A., & Samulski, R. J. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.2515 · Cited by 38
“The recent mapping of surface-exposed antigenic epitopes using cryo-EM (Gurda et al., 2012, 2013; Harbison et al., 2012; Lerch et al., 2012) is likely to enable structure-driven genetic manipulation of different cardiotropic AAV serotypes to generate novel, neutralizing antibody escape variants…”
BackgroundEmmanuel, S. N., Smith, J. K., Hsi, J., Tseng, Y.-S., Kaplan, M., Mietzsch, M., Chipman, P. R., Asokan, A., McKenna, R., & Agbandje‐McKenna, M. (2021) · Journal of Virology · doi:10.1128/jvi.01251-21 · Cited by 36
Self-citationGene therapy for genetic diseases: challenges and future directions
Beibei, Q. I. E., Tuo, J., Chen, F., Ding, H., & Lyu, L. (2025) · MedComm · doi:10.1002/mco2.70091 · Cited by 45
Emmanuel, S. N., Mietzsch, M., Tseng, Y.-S., Smith, J. K., & Agbandje‐McKenna, M. (2021) · Viral Immunology · doi:10.1089/vim.2020.0022 · Cited by 33
“In contrast to ADK5a and ADK5b neither the Fabs or IgG of the 3C5 antibody inhibited viral transduction (55) consistent with lack of overlap with the receptor attachment site at the 3-fold axes or 5-fold region proposed to be involved in PLA2 function (16,45,137).”
BackgroundInfluentialSelf-citationNovel Therapies for Heart Failure – Where Do They Stand? –
Greenberg, B. (2016) · Circulation Journal · doi:10.1253/circj.cj-16-0742 · Cited by 34
Silveria, M., Large, E. E., Zane, G. M., White, T., & Chapman, M. S. (2020) · Viruses · doi:10.3390/v12111326 · Cited by 32
“3C5 only showed IgG neutralization at high concentrations (100,000 fold excess AB:AAV) [40].”
BackgroundZdechlik, A. C., He, Y., Aird, E. J., Gordon, W. R., & Schmidt, D. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00790 · Cited by 31
Tseng, Y.-S., Vliet, K. V., Rao, L., McKenna, R., Byrne, B. J., Asokan, A., & Agbandje-McKenna, M. (2016) · Journal of Virological Methods · doi:10.1016/j.jviromet.2016.07.009 · Cited by 28
“However, in another study using subcutaneous immunization in Balb/c mice, a spectrum of MAb isotypes were selected, including IgG1, IgG2a, IgG2b, IgG3, and IgM (Harbison et al. 2012).”
BackgroundSelf-citationCreating an arsenal of Adeno-associated virus (AAV) gene delivery stealth vehicles
Smith, J. K., & Agbandje‐McKenna, M. (2018) · PLoS Pathogens · doi:10.1371/journal.ppat.1006929 · Cited by 26
Self-citationLotfinia, M., Abdollahpour‐Alitappeh, M., Hatami, B., Zali, M. R., & Karimipoor, M. (2019) · Clinical and Experimental Medicine · doi:10.1007/s10238-019-00557-8 · Cited by 28
New and improved AAVenues: current status of hemophilia B gene therapy
Brimble, M. A., Reiss, U. M., Nathwani, A. C., & Davidoff, A. M. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1106475 · Cited by 22
Daniel, H. D. J., Kumar, S., Kannangai, R., Lakshmi, K. M., Agbandje‐McKenna, M., Coleman, K. E., Srivastava, A., Srivastava, A., & Abraham, A. M. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.258 · Cited by 19
“10,11 The humoral immune response against AAV is classi-fied into neutralizing and binding antibodies.”
Self-citationHeller, G., Bradbury, A. M., Sands, M. S., & Bongarzone, E. R. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.09.017 · Cited by 23
Hu, G., Silveria, M., Zane, G. M., Chapman, M. S., & Stagg, S. M. (2022) · Journal of Virology · doi:10.1128/jvi.00106-22 · Cited by 16
“, antibodies recognizing one serotype do not cross-react with others (35, 37).”
BackgroundLarge, E. E., & Chapman, M. S. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1116896 · Cited by 18
“Pragmatically, it is easier to work with purified samples, and so our understanding of what might happen in an in vivo human polyclonal response is by extrapolation from a subset of the 25 mAb raised to 9 serotypes, many of which are neutralizing (Wobus et al., 2000; Kuck et al., 2007; Gurda et al., 2012; Harbison et…”
BackgroundSierra-Delgado, J. A., Likhite, S. B., Bautista‐Niño, P. K., Gómez‐Ochoa, S. A., Echeverría, L. E., Guío, E., Vargas, C. I., Serrano, N. C., Meyer, K., & Rincón, M. Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065579 · Cited by 13
“Unfortunately, despite the advances made in the immune evasion capabilities of these engineered vectors, it has been observed that many of the modifications in their capsid structure may compromise their functionality [19,20].”
BackgroundNeutralisation of adeno-associated virus transduction by human vitreous humour
Andrzejewski, S., Moyle, P. M., Stringer, B. W., Steel, J. C., & Layton, C. J. (2021) · Gene Therapy · doi:10.1038/s41434-020-0162-8 · Cited by 10
Daniel, H. D. J., Kumar, S., Kannangai, R., Farzana, J., Joel, J. N., Abraham, A., Lakshmi, K. M., Agbandje‐McKenna, M., Coleman, K. E., Srivastava, A., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27859 · Cited by 6
“However, the development of naturally occurring anti‐AAV antibodies in humans against the capsid antigen is a significant impediment to the success of using AAV as a gene therapy vector.(9,10) The prevalence of neutralizing antibodies (NAb) to the different serotypes of AAV varies from 3.”
BackgroundSelf-citationExploring protein orthogonality in immune space: a case study with AAV and Cas9 orthologsPreprint
Moreno, A. M., Palmer, N. D., Alemán, F., Chen, G., Pla, A., Chew, W. L., Law, M., & Mali, P. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/245985 · Cited by 6
Structures and functions of the limited natural polyclonal antibody response to parvovirus infection
Adu, O. F., Lee, H., Früh, S. P., Schoenle, M. V., Weichert, W. S., Flyak, A. I., Hafenstein, S. L., & Parrish, C. R. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2423460122 · Cited by 7
Self-citationAdeno-Associated Vectors for Gene Delivery to the Nervous System
Mulcahy, P. J., Binny, C., Muszynski, B., Karyka, E., & Azzouz, M. (2015) · Neuromethods · doi:10.1007/978-1-4939-2306-9_1 · Cited by 3
The hepatic Odyssey of Adeno-associated virus: from gene delivery to long-term outcomes
Simini, G., & Batty, P. A. (2025) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2025.08.028 · Cited by 3
Hoad, M., Nematollahzadeh, S., Roby, J. A., Alvisi, G., & Forwood, J. K. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101630 · Cited by 3
Hu, G., Silveria, M., Chapman, M. S., & Stagg, S. M. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.10.475736 · Cited by 3
Daniel, H. D. J., Farzana, J., Kannangai, R., Kumar, S., Lakshmi, K. M., Jashal, C. B., Dhamne, H., Lahoti, V., Kanjwani, D., Abraham, A., et al. (2025) · Human Gene Therapy · doi:10.1177/10430342251366208 · Cited by 2
“10,11 The humoral immune response against AAV is classi fi ed into neutralizing antibody (NAb) and non-NAb.”
Maurizi, N., Hong, K. N., Silver, E., Patel, U., & ADLER, E. D. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.08.340 · Cited by 6
Cre Recombinase Mediates the Removal of Bacterial Backbone to Efficiently Generate rSV40
Shi, X., Ykema, M., Hazenoot, J., ten Bloemendaal, L., Mancini, I., Odijk, M., de Haan, P., & Bosma, P. J. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.02.010 · Cited by 2
Serotype 8 Capsid of Adeno-Associated Virus Mapping a Neutralizing Epitope onto the
Agbandje‐McKenna, M., Baker, T. S., Kleinschmidt, J. A., Naumer, M., Olson, N. H., Ng, R., Gurda, L., Raupp, C., & Popa-Wagner, R. (2012)
Self-citationAPPLICATION OF RADIOISOTOPES AND IONIZING RADIATION FOR INSECT CONTROL.
Kloft, W., Suess, A., & Haisch, A. (1971) · OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information)
Silveria, M. (2022) · MOspace Institutional Repository (University of Missouri) · doi:10.32469/10355/94095
Metadata
- Authors
- Harbison, C. E., Weichert, W. S., Gurda, B. L., Chiorini, J. A., Agbandje-McKenna, M., & Parrish, C. R.
- Affiliations
- Cornell University (US)
- University of Florida (US)
- National Institutes of Health (US)
- Department of Biochemistry and Molecular Biology, University of Florida, Gainesville, FL 32610, USA
- Venue
- Journal of General Virology
- Publisher
- Microbiology Society
- Published
- 2012-02-01
- Volume
- 93
- Issue
- 2
- Pages
- 347-355
- ISSN
- 0022-1317 (ISSN-L)
- 1465-2099
- PMC
- PMC3352341
- OpenAlex
- W2127304128
- Cited by
- 54
- References
- 74
- Citations by year
- 2025: 6 · 2024: 1 · 2023: 3 · 2022: 6 · 2021: 2 · 2020: 5 · 2019: 5 · 2018: 4 · 2017: 3 · 2016: 3 · 2015: 5 · 2014: 4 · 2013: 3 · 2012: 3
- FWCI
- 1.99
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of General Virology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (P01HL059412)
- National Institute of Allergy and Infectious Diseases (R21AI072341)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- adeno-associated virus, AAV1, AAV5, monoclonal antibodies, antibody neutralization, cross-reactivity, viral capsid, gene delivery vectors, receptor binding inhibition, Fab fragment, vaccination strategies
- MeSH terms
- Dependovirus, Animals, Antibodies, Monoclonal, Antibodies, Viral, Cross Reactions, Immunoglobulin G, Neutralization Tests, Mice, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.